Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease
Por:
E. KNECHT, O. CRIADO-GARCIA, C. AGUADO, J. GAYARRE, L. DURAN-TRIO, A. GARCIA-CABRERO, S. VERNIA, B. SAN MILLAN, M. HEREDIA, C. ROMA-MATEO, S. MOURON, L. JUANA-LOPEZ, M. DOMINGUEZ, C. NAVARRO, J. SERRATOSA, M. SANCHEZ, P. SANZ, P. BOVOLENTA and S. DE CORDOBA
Publicada:
1 abr 2012
Resumen:
Lafora disease (LD), a fatal neurodegenerative disorder characterized by intracellular inclusions called Lafora bodies (LBs), is caused by recessive loss-of-function mutations in the genes encoding either laforin or malin. Previous studies suggested a role of these proteins in regulating glycogen biosynthesis, in glycogen dephosphorylation and in the modulation of intracellular proteolytic systems. However, the contribution of each of these processes to LD pathogenesis is unclear. Here we review our recent finding that dysfunction of autophagy is a common feature of both laforin-and malin-deficient mice, preceding other pathological manifestations. We propose that autophagy plays a primary role in LD pathogenesis and is a potential target for its treatment.
Filiaciones:
:
Ctr Invest Principe Felipe, Lab Cellular Biol, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
O. CRIADO-GARCIA:
CSIC, Ctr Invest Biol, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
:
Ctr Invest Principe Felipe, Lab Cellular Biol, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
J. GAYARRE:
CSIC, Ctr Invest Biol, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
L. DURAN-TRIO:
CSIC, Ctr Invest Biol, Madrid, Spain
Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
A. GARCIA-CABRERO:
Fdn Jimenez Diaz, Inst Invest Sanitaria, Lab Neurol, E-28040 Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
S. VERNIA:
CSIC, Inst Biomed Valencia, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
B. SAN MILLAN:
Complejo Hosp Univ Vigo Meixoeiro, Serv Anat Patol & Neuropatol, Vigo, Spain
M. HEREDIA:
CSIC, Inst Biomed Valencia, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
:
CSIC, Inst Biomed Valencia, Valencia, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
S. MOURON:
CSIC, Ctr Invest Biol, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
L. JUANA-LOPEZ:
CSIC, Ctr Invest Biol, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
M. DOMINGUEZ:
Inst Invest Carlos III, Ctr Nacl Microbiol, Serv Inmunol Microbiana, Majadahonda Madrid, Spain
C. NAVARRO:
Complejo Hosp Univ Vigo Meixoeiro, Serv Anat Patol & Neuropatol, Vigo, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
J. SERRATOSA:
Fdn Jimenez Diaz, Inst Invest Sanitaria, Lab Neurol, E-28040 Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
M. SANCHEZ:
Fdn Jimenez Diaz, Inst Invest Sanitaria, Lab Neurol, E-28040 Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
P. SANZ:
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
P. BOVOLENTA:
Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
S. DE CORDOBA:
CSIC, Ctr Invest Biol, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
|